Dr. Paul Parren - Gilde Healthcare

team
Venture&Growth

All team members
Dr. Paul Parren
Operational Partner
The Netherlands

Dr. Paul Parren

Operational Partner

Paul Parren is an internationally recognized antibody drug innovator and developer. Paul was Head of Preclinical Development and Research at Genmab (2002-2017), translating antibody biology successfully into immunotherapies from discovery to the clinic, including approved therapeutic antibodies ofatumumab and daratumumab, as well as establishing validated antibody platform technologies. He is a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden, the Netherlands, board member of The Antibody Society and was an Associate Professor at The Scripps Research Institute in La Jolla, California. He holds a PhD in Molecular Immunology from the University of Amsterdam.

Paul assists Gilde in the evaluation of investment opportunities and is also acting as Executive Vice President and Head of Research & Development for Gilde’s portfolio company Lava Therapeutics.

Tristan Maguet

Associate Therapeutics
Venture&Growth
Tristan Maguet joined Gilde in 2022 and focuses on the Therapeutics sector. He is involved in deal sourcing, due diligence and portfolio management. Prior to joining Gilde, Tristan was an Investment Analyst at a Mutual Fund...

Edward Hanlon

Senior Associate Healthtech
Venture&Growth
Edward Hanlon joined Gilde Healthcare in 2020 in the Cambridge office and focuses on Healthtech. Prior to joining Gilde, Edward worked in advisory for Health Advances, a consulting firm operating across healthcare sectors in medical...

Anastasia Budinskaya

Associate HealthTech
Venture&Growth
Anastasia Budinskaya joined Gilde Healthcare in 2022 and focuses on Healthtech and Medtech investing.  Before joining Gilde, Anastasia was a Scientific Leader in Neurology at GE Healthcare. She transitioned a new product into the GE Pharmaceutical Diagnostics...